The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Ascentage Pharma Group International (NASDAQ:AAPG) is one of the

10 Stocks That Have the Potential to Rise 1000%.

On May 31, 2026, Ascentage Pharma Group International (NASDAQ:AAPG) announced Phase Ib results evaluating olverembatinib in combination with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia. The data were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology Annual Meeting. Ascentage Pharma said 91% of patients achieved complete response or complete response with incomplete hematologic recovery, while 67% achieved BCR::ABL1 negativity by PCR and 80% achieved MRD negativity by flow cytometry.

Also on May 31, Ascentage Pharma Group International (NASDAQ:AAPG) presented its first dataset for alrizomadlin, an MDM2-p53 inhibitor, as monotherapy or in combination with lisaftoclax in pediatric patients with relapsed/metastatic rhabdomyosarcoma or other soft-tissue sarcomas. In the monotherapy arm, one patient with refractory RMS achieved a complete response. In the combination arm, the ORR was 23.5% among 17 response-evaluable pediatric patients with relapsed/refractory solid tumors, while the disease control rate was 70.6%.

Photo by National Cancer Institute on Unsplash

In April, Deutsche Bank initiated coverage of Ascentage Pharma Group International (NASDAQ:AAPG) with a Buy rating and a $40 price target. Deutsche Bank cited two “de-risked, commercially validated” mechanisms in olverembatinib and lisaftoclax, and said lisaftoclax is positioned for continued commercial traction in China.

Ascentage Pharma Group International (NASDAQ:AAPG) develops therapies for cancers, chronic hepatitis B virus, and age-related diseases in Mainland China.

While we acknowledge the potential of AAPG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.